<DOC>
	<DOCNO>NCT00003528</DOCNO>
	<brief_summary>Phase I trial study effectiveness raltitrexed treat child refractory acute leukemia . Drugs use chemotherapy use different way stop tumor cell divide stop growing die</brief_summary>
	<brief_title>Raltitrexed Treating Children With Refractory Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity raltitrexed give three week child refractory acute leukemia . II . Determine incidence severity toxic effect regimen patient . III . Determine safe tolerable dose raltitrexed , administer manner , use phase II study . IV . Determine pharmacokinetics regimen patient . V. Determine plasma 2 ' deoxyuridine concentration associate raltitrexed toxicity pharmacokinetics . VI . Evaluate antitumor activity raltitrexed recurrent leukemia . OUTLINE : This dose escalation study . Patients receive raltitrexed intravenously 15 minute weekly 3 week follow 1 week rest . Treatment continue absence disease progression unacceptable toxicity . In absence dose-limiting toxicity ( DLT ) first cohort 6 patient treat , subsequent cohort 6 patient receive escalate dos raltitrexed schedule . If DLT occur 2 6 patient give dose level , dose escalation cease next low dose declare maximum tolerated dose . Patients follow every 6 month 4 year , annually thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Raltitrexed</mesh_term>
	<criteria>Histologically cytologically proven acute leukemia ( M3 marrow ) refractory conventional therapy effective therapy exist No CNS leukemia No solid tumor Performance status : Karnofsky 50100 % OR Lansky least 50 ( infant ) Life expectancy : At least 8 week Bilirubin le 1.5 mg/dL SGPT le 5 time normal Normal creatinine age OR GFR least 70 mL/min No significant systemic illness infection No significant third space fluid collection Not pregnant nursing Recovered acute toxic effect prior immunotherapy At least 6 month since prior bone marrow transplant evidence graftversushost disease At least 10 day since prior biologic therapy At least 1 week since prior growth factor At least 2 week since prior myelosuppressive chemotherapy ( 6 week nitrosourea ) recover No concurrent steroid Recovered acute toxic effect prior radiotherapy At least 2 week since prior local palliative radiotherapy ( small port ) At least 6 month since prior substantial bone marrow radiation No concurrent anticancer therapy investigational agent No concurrent nonsteroidal antiinflammatory agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>